Immix Biopharma (IMMX) Cash from Operations (2021 - 2026)
Immix Biopharma (IMMX) posted Cash from Operations of 9827193.0 for Q1 2026, up 10.9% sequentially from 11029607.0 in Q4 2025, and down 483.17% YoY from 2564723.42 in Q1 2025.
Immix Biopharma (IMMX) Cash from Operations (2021 - 2026) Analysis & Trends
Immix Biopharma has reported Cash from Operations for 6 years, with the latest figure at 9827193.0 in Q1 2026.
- Quarterly Cash from Operations fell 483.17% year-over-year to 9827193.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32072357.0 (down 157.54% YoY) and the FY2025 annual result came in at 23930304.0, down 63.96% from the prior year.
- Cash from Operations rose to 9827193.0 in Q1 2026 per IMMX's latest filing, from 11029607.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 547066.0 in Q2 2022 and troughed at 11029607.0 in Q4 2025.
- A 5-year average of 3948961.18 and a median of 3515346.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 2781.24% in 2022, then jumped 55.97% in 2025.
- Over 5 years, Cash from Operations stood at 3903926.0 in 2022, then soared by 31.42% to 2677437.0 in 2023, then jumped by 44.87% to 1476198.0 in 2024, then sank by 647.16% to 11029607.0 in 2025, then grew by 10.9% to 9827193.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 9827193.0, 11029607.0, and 5905776.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | -11.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.74 Mn |
| Jun 30, 2026 | -11.74 Mn |
| Mar 31, 2026 | -9.83 Mn |
| Mar 31, 2026 | -9.83 Mn |
| Dec 31, 2025 | -11.03 Mn |
| Dec 31, 2025 | -11.03 Mn |
| Sep 30, 2025 | -5.91 Mn |
| Sep 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -5.31 Mn |
| Jun 30, 2025 | -5.31 Mn |
| Mar 31, 2025 | -1.69 Mn |
| Mar 31, 2025 | -1.69 Mn |
| Dec 31, 2024 | -1.48 Mn |
| Dec 31, 2024 | -1.48 Mn |
| Sep 30, 2024 | -4.04 Mn |
| Sep 30, 2024 | -4.04 Mn |
| Jun 30, 2024 | -5.26 Mn |
| Jun 30, 2024 | -5.26 Mn |
| Mar 31, 2024 | -3.83 Mn |
| Mar 31, 2024 | -3.83 Mn |